Harnessing the power of RNA modification

Watch full video

1st in Class Inhibitors of RNA Modifying Enzymes (RME) with the potential to Treat Cancer and Other Diseases

STORM Therapeutics (STORM) a clinical stage biotechnology company focused on discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RME) for oncology and other diseases. There are more than 150 RNA modifications reported and approximately 300 RNA modifying enzymes which represent novel therapeutic targets.

Read more

RNA modifying enzymes

RNA (ribonucleic acid) is the only direct product of the human genome and one type of RNA, mRNA, acts as the template to which transfer RNAs (tRNA) bind to drive the synthesis of all proteins, the molecular machines of the cell. RNA is also known to be a key player in cellular decision-making, particularly in the form of non-coding RNA (ncRNA) such as microRNA, piRNA and long non-coding RNA.

Read more


STORM Therapeutics to present the discovery of lead clinical candidate STC-15 at the American Chemical Society Fall 2023 Conference

STORM Therapeutics publishes data in Cancer Discovery showing induction of anti-tumour immunity by METTL3 inhibition


20 - 24th October 2023 | Madrid, Spain

European Society for Medical Oncology (ESMO) Congress 2023